Customize Your Learning Experience!

Mix-and-match sessions from these additional co-located conferences at no additional cost:

• Recombinant Protein & Complex Biologic Development & Production
• Analytical Technologies for Biotherapeutic Development
• Biobetters & Biosimilars: Technologies & Development Strategies

Arrive early so you can attend the first half of the week, Feb. 27-28 for these conferences:

• Process & Product Validation
• Technology Transfer for Biopharmaceuticals
• Outsourcing Manufacturing of Biopharmaceuticals
• Biopharmaceutical Raw Materials throughout the Product Lifecycle
• Viral Safety for Biologicals

Get the Most Out of Your Budget with the "All Access Pass" to Attend Sessions from All 9 Conferences

View the Agenda-At-A-Glance for the Entire Week.

Special Discounted Hotel Rate

Special Discounted Hotel Rate Available Until February 3, 2012.
To book your room, call 1-800-HILTONS and mention that you are an IBC attendee at this event.

Request Your 2012 Event Updates

Join the priority contact list today!

See Who Attended in 2011

Read a sample of who attended the conference in 2011.
Updated: March 16, 2011

The Antibody Development & Production conference offers you the highest quality and most in-depth coverage of the latest technical and scientific advances in bioprocessing to help companies (of all sizes) improve the speed, quality and cost of developing and producing antibodies. Exclusive case studies delivering the latest data together with strategic discussion forums allow the industry's leading scientists, engineers and executives to collectively collaborate and provide solutions to their most pressing challenges.

"IBC continues to put together a well organized series of conferences that cover the key topics and areas of interest across the biotech industry. They provide an excellent forum to bring together leading scientists and companies to exchange ideas and create networking contacts." - William D. Taylor, Director, Business Development, Pfenex

This Conference Will Help You:

• Examine the next wave of drivers for process innovation, integration and optimization
• Learn comprehensive approaches to capitalize on high-titer processes

2012 Sessions Will Include Proven Approaches, Case Studies and Unpublished Data on:

• Next Wave of Process Development - Improvements through Innovation, Integration and Optimization
• Implementation of Novel, Cost Effective Approaches to Capitalize on High Titer Processes
• Improving the Interface Between Upstream and Downstream Processing
• Impact of Antibody Engineering on Development and Production
• Advances in Cell Line Selection, Development and Engineering
• Overcoming Challenges of Developing and Delivering High Concentration Formulations
• Improving Product Quality in Process Development
• New Approaches and Strategies for Characterization and Comparability
• Development and Production of Drug Conjugates
• Development and Production of Next Generation and Novel Molecules

Find Out How the Industry is Addressing these Critical Topics:

Comparability Within A Single Product Differs from Biosimilarity Between Two Products
Anthony S. Lubiniecki, Sc.D.
Johnson & Johnson Pharmaceutical R&D, Inc.

Path to Approval for Antibody Drug Conjugates
Morris Rosenberg, D.Sc.
Seattle Genetics

Continuous Bioprocessing for Production of Biopharmaceuticals
Weichang Zhou, Ph.D.
Genzyme, a Sanofi Company

Application of Quality by Design Approach in Viral Clearance Studies: Be Prepared and Set a Realistic Expectation
Dayue Chen, Ph.D.
Eli Lilly and Company

Developing High Dose Monoclonal Antibody Formulations for SC Delivery
Steven J. Shire, Ph.D.
Genentech, Inc.

Special thanks to the Scientific Advisory Committee for their help in developing this program.
» View the list of committee members